TY - JOUR
T1 - Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma – Preliminary CT-based radiomic analysis (POLAR Liver 1.1)
AU - Iezzi, Roberto
AU - Casa, C.
AU - Posa, A.
AU - Cornacchione, Patrizia
AU - Carchesio, F.
AU - Boldrini, Luca
AU - Tanzilli, A.
AU - Cerrito, L.
AU - Fionda, B.
AU - Longo, V.
AU - Miele, Luca
AU - Lancellotta, V.
AU - Cellini, Francesco
AU - Tran, H. E.
AU - Ponziani, Francesca Romana
AU - Giuliante, Felice
AU - Rapaccini, G. L.
AU - Grieco, A.
AU - Pompili, Maurizio
AU - Gasbarrini, Antonio
AU - Valentini, V.
AU - Gambacorta, Maria Antonietta
AU - Tagliaferri, Luca
AU - Manfredi, Riccardo
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: The objective of this study is to find a contrast-enhanced CT-radiomic signature to predict clinical incomplete response in patients affected by hepatocellular carcinoma who underwent locoregional treatments. PATIENTS AND METHODS: 190 patients affected by hepatocellular carcinoma treated using focal therapies (radiofrequency or microwave ablation) from September 2018 to October 2020 were retrospectively enrolled. Treatment response was evaluated on a per-target-nodule basis on the 6-months follow-up contrast-enhanced CT or MR imaging using the mRECIST criteria. Radiomics analysis was performed using an in-house developed open-source R library. Wilcoxon-Mann-Whitney test was applied for univariate analysis; features with a p-value lower than 0.05 were selected. Pearson correlation was applied to discard highly correlated features (cut-off=0.9). The remaining features were included in a logistic regression model and receiver operating characteristic curves; sensitivity, specificity, positive and negative predictive value were also computed. The model was validated performing 2000 bootstrap resampling. RESULTS: 56 treated lesions from 42 patients were selected. Treatment responses were: complete response for 26 lesions (46.4%), 18 partial responses (32.1%), 10 stable diseases (17.9%), 2 progression diseases (3.6%). Area-Under-Curve value was 0.667 (95% CI: 0.527-0.806); accuracy, sensitivity, specificity, positive and negative predictive values were respectively 0.66, 0.85, 0.50, 0.59 and 0.79. CONCLUSIONS: This contrast-enhanced CT-based model can be helpful to early identify poor responder’s hepatocellular carcinoma patients and personalize treatments.
AB - OBJECTIVE: The objective of this study is to find a contrast-enhanced CT-radiomic signature to predict clinical incomplete response in patients affected by hepatocellular carcinoma who underwent locoregional treatments. PATIENTS AND METHODS: 190 patients affected by hepatocellular carcinoma treated using focal therapies (radiofrequency or microwave ablation) from September 2018 to October 2020 were retrospectively enrolled. Treatment response was evaluated on a per-target-nodule basis on the 6-months follow-up contrast-enhanced CT or MR imaging using the mRECIST criteria. Radiomics analysis was performed using an in-house developed open-source R library. Wilcoxon-Mann-Whitney test was applied for univariate analysis; features with a p-value lower than 0.05 were selected. Pearson correlation was applied to discard highly correlated features (cut-off=0.9). The remaining features were included in a logistic regression model and receiver operating characteristic curves; sensitivity, specificity, positive and negative predictive value were also computed. The model was validated performing 2000 bootstrap resampling. RESULTS: 56 treated lesions from 42 patients were selected. Treatment responses were: complete response for 26 lesions (46.4%), 18 partial responses (32.1%), 10 stable diseases (17.9%), 2 progression diseases (3.6%). Area-Under-Curve value was 0.667 (95% CI: 0.527-0.806); accuracy, sensitivity, specificity, positive and negative predictive values were respectively 0.66, 0.85, 0.50, 0.59 and 0.79. CONCLUSIONS: This contrast-enhanced CT-based model can be helpful to early identify poor responder’s hepatocellular carcinoma patients and personalize treatments.
KW - Ablation
KW - Hepatocellular carcinoma
KW - Interventional oncology
KW - Personalized medicine
KW - Radiomic
KW - Ablation
KW - Hepatocellular carcinoma
KW - Interventional oncology
KW - Personalized medicine
KW - Radiomic
UR - https://publicatt.unicatt.it/handle/10807/325260
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85129781354&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85129781354&origin=inward
U2 - 10.26355/eurrev_202204_28620
DO - 10.26355/eurrev_202204_28620
M3 - Article
SN - 1128-3602
VL - 26
SP - 2891
EP - 2899
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
IS - 8
ER -